Search Results - systemic+lupus+erythematosus

3 Results

Sort By:

JC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. For example, more than five percent (5%) of AIDS patients develop PML. Additionally, these conditions include, but are not limited to, cancers such as leukemias and lymphomas, organ transplants...

Published: 10/28/2024 | Inventor(s): Caroline Ryschkewitsch, Eugene Major

Keywords(s): assay, DA4BXX, DA4XXX, DAXXXX, DDXXXX, Detection, DEXXXX, DNA, DXXXXX, JC, Proficiency, Progressive multifocal leukoencephalopathy, QPCR, Samples', STANDARDS, Systemic lupus erythematosus, test, virus

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Infectious Disease

Cell Based Immunotherapy

The invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance...

Published: 10/28/2024 | Inventor(s): Ethan Shevach, Dat Tran

Keywords(s): 2, ACTIVATED, ALLOWS, Aplastic anemia, Aplastic anemia, idiopathic; Aplastic anemia, Associated, CD121b, CELL-BASED, Cells, CULTURES, EXPANSION, Expression, FOXP3+, Generate, Graft versus host disease, Human, IB3XXX, IBXXXX, Idiopathic thrombocytopenic purpura, IL-l, Immunotherapy, IXXXXX, LAP, Latency, NUMBERS, Patent Category - Biotechnology, Peptide, purification, RECEPTOR, Regulatory, SELECTIVE, Sufficient, Systemic lupus erythematosus, T, Their, Thrombocytopenic purpura, autoimmune, TYPE

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials

TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability

The disclosed invention provides materials and methods to treat granulocytopenia (low white cell count in the blood) which is characterized by a reduced number of granulocytes (relative) or an absence of granulocytes (absolute). This condition is commonly associated with cancer chemotherapy, but is seen less frequently in a number of conditions including...

Published: 10/28/2024 | Inventor(s): Wi Lai, Perry Blackshear, Ester Carballo

Keywords(s): Aplastic anemia, Deadenylation, Duke DNA Project, GM-CSF, Granulocytopenia, IB6XXX, IBXXXX, IXXXXX, REGULATOR, STABILITY, Systemic lupus erythematosus, TTP, UA1XXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases